NASDAQ:VTVT

vTv Therapeutics (VTVT) Stock Forecast, Price & News

$0.45

+0.01 (+2.27%)

(As of 09/25/2023 ET)

Compare

Today's Range: $0.44
▼
$0.46
50-Day Range: $0.42
▼
$0.74
52-Week Range: $0.41
▼
$1.05

Volume: 80,239 shs
Average Volume: 136,285 shs
Market Capitalization: $47.07 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

vTv Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,233.0% Upside
$6.00 Price Target
Short Interest: Healthy
4.42% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

829th out of 962 stocks

Pharmaceutical Preparations Industry

394th out of 451 stocks

3.5

Analyst's Opinion

Consensus Rating
vTv Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, vTv Therapeutics has a forecasted upside of 1,233.0% from its current price of $0.45.
Amount of Analyst Coverage
vTv Therapeutics has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.42% of the float of vTv Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
vTv Therapeutics has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in vTv Therapeutics has recently decreased by 13.57%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
vTv Therapeutics does not currently pay a dividend.
Dividend Growth
vTv Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VTVT.

0.7

News and Social Media Coverage

News Sentiment
vTv Therapeutics has a news sentiment score of -0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for vTv Therapeutics this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 1 people have added vTv Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, vTv Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.80% of the stock of vTv Therapeutics is held by insiders.
Percentage Held by Institutions
Only 3.36% of the stock of vTv Therapeutics is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of vTv Therapeutics is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of vTv Therapeutics is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About vTv Therapeutics (NASDAQ:VTVT) Stock

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

VTVT Price History

30 days | 90 days | 365 days | Advanced Chart

VTVT Stock News Headlines

September 24, 2023 | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com

September 18, 2023 | finance.yahoo.com

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

September 26, 2023 | Altimetry (Ad)

Surprising "Twist" Hands Biden Landslide Re-election?

This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.

September 16, 2023 | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com

August 24, 2023 | finance.yahoo.com

Is vTv Therapeutics Inc (VTVT) Modestly Undervalued?

August 16, 2023 | finance.yahoo.com

vTv Therapeutics reports $5.6 million net loss as prepares for reverse stock split to remain on Nasdaq

August 12, 2023 | finanznachrichten.de

vTv Therapeutics Inc.: vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

August 11, 2023 | finance.yahoo.com

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

September 26, 2023 | Altimetry (Ad)

Surprising "Twist" Hands Biden Landslide Re-election?

This could make it harder than ever to hang onto the money you make as Progressives gain power, and America slides further towards Socialism.

August 10, 2023 | finance.yahoo.com

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

August 6, 2023 | msn.com

Nearly half of U.S. adults want weight-loss drugs – KFF poll

July 12, 2023 | finance.yahoo.com

VTVT - vTv Therapeutics Inc.

July 6, 2023 | msn.com

vTv Therapeutics Inc - (VTVT) Price Target Decreased by 33.33% to 2.04

June 16, 2023 | marketwatch.com

vTv Therapeutics Partner Licenses Exclusive Rights to Intellectual Property for Azeliragon

June 16, 2023 | tmcnet.com

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a

June 16, 2023 | finance.yahoo.com

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

June 15, 2023 | finance.yahoo.com

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

June 6, 2023 | bizjournals.com

As it advances its Type 1 Diabetes treatment, vTv Therapeutics increases cash position, decreases net loss in Q1

May 24, 2023 | finance.yahoo.com

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 12, 2023 | finanznachrichten.de

vTv Therapeutics Inc.: vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

May 12, 2023 | finance.yahoo.com

vTv Therapeutics Insider Ups Holding During Year

May 12, 2023 | finance.yahoo.com

vTv Therapeutics Insider Ups Holding During Year \

May 11, 2023 | finance.yahoo.com

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

April 28, 2023 | morningstar.com

vTv Therapeutics Inc Class A

April 20, 2023 | finance.yahoo.com

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

April 18, 2023 | msn.com

Promising Upsides on these Biotech Penny Stocks

March 25, 2023 | finance.yahoo.com

3 Pharma Stocks That Could Benefit from Global Healthcare Trends

See More Headlines

Receive VTVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTVT Company Calendar

Last Earnings: 8/11/2023
Today: 9/25/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VTVT
CUSIP: N/A
CIK: 1641489
Web: www.vtvtherapeutics.com
Phone: (336) 841-0300
Fax: 336-841-0310
Employees: 13
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.00
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +1,221.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,160,000.00
Net Margins: N/A
Pretax Margin: -272,700.00%
Return on Equity: N/A
Return on Assets: -63.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.50
Quick Ratio: 1.50

Sales & Book Value

Annual Sales: $2.02 million
Price / Sales: 23.51
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.10) per share
Price / Book: -4.54

Miscellaneous

Outstanding Shares: 104,580,000
Free Float: 103,740,000
Market Cap: $47.49 million
Optionable: Not Optionable
Beta: -1.13

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Jonathan L. Isaacsohn FACC (Age 69)
M.D., Exec. Chairperson

Mr. Paul J. Sekhri M.Sc. (Age 65)
MSc, CEO, Pres & Director
Comp: $483.43k

Mr. Steven Tuch M.B.A. (Age 54)
Exec. VP & CFO
Comp: $449.16k

Mr. Barry Brown (Age 62)
Chief Accounting Officer
Comp: $311.98k

Mr. Richard S. Nelson (Age 53)
Exec. VP of Corp. Devel. & Director
Comp: $201.08k

Dr. Carmen Valcarce Ph.D.
Chief Scientific Officer & Exec. VP

Vanessa McDade
Chief Admin. Officer

Ms. Elizabeth M. Keiley (Age 57)
Exec. VP & Gen. Counsel

Key Competitors

View All Competitors

Insiders

John A Fry
Bought 20,539 shares on 11/28/2022
Total: $17,047.37 ($0.83/share)

View All Insider Transactions

VTVT Stock - Frequently Asked Questions

Should I buy or sell vTv Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VTVT shares.
View VTVT analyst ratings or view top-rated stocks.
What is vTv Therapeutics' stock price forecast for 2023?: 1 brokerages have issued 1 year price objectives for vTv Therapeutics' shares. Their VTVT share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 1,221.3% from the stock's current price.
View analysts price targets for VTVT or view top-rated stocks among Wall Street analysts.
How have VTVT shares performed in 2023?: vTv Therapeutics' stock was trading at $0.6628 on January 1st, 2023. Since then, VTVT shares have decreased by 31.5% and is now trading at $0.4541.
View the best growth stocks for 2023 here.
When is vTv Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our VTVT earnings forecast.
How were vTv Therapeutics' earnings last quarter?: vTv Therapeutics Inc. (NASDAQ:VTVT) issued its earnings results on Friday, August, 11th. The biotechnology company reported ($0.07) earnings per share for the quarter.
What other stocks do shareholders of vTv Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA).

When did vTv Therapeutics IPO?: (VTVT) raised $125 million in an IPO on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.
What is vTv Therapeutics' stock symbol?: vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."
How do I buy shares of vTv Therapeutics?: Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is vTv Therapeutics' stock price today?: One share of VTVT stock can currently be purchased for approximately $0.45.
How much money does vTv Therapeutics make?: vTv Therapeutics (NASDAQ:VTVT) has a market capitalization of $47.49 million and generates $2.02 million in revenue each year. The biotechnology company earns $-19,160,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.
How can I contact vTv Therapeutics?: vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The official website for the company is www.vtvtherapeutics.com. The biotechnology company can be reached via phone at (336) 841-0300, via email at ir@vtvtherapeutics.com, or via fax at 336-841-0310.

This page (NASDAQ:VTVT) was last updated on 9/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial